Spots Global Cancer Trial Database for tremelimumab
Every month we try and update this database with for tremelimumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | NCT02485990 | Primary Periton... | Tremelimumab Olaparib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | NCT02340975 | Gastric or Gast... | MEDI4736 + trem... MEDI4736 + trem... MEDI4736 Tremelimumab MEDI4736+tremel... MEDI4736 + trem... | 18 Years - 99 Years | MedImmune LLC | |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy | NCT03703297 | Small Cell Lung... | Durvalumab Tremelimumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | NCT03237377 | Non-Small Cell ... | Durvalumab Tremelimumab Thoracic Radiat... lobectomy Standard of car... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | NCT02535078 | Malignant Melan... | Tebentafusp (IM... durvalumab tremelimumab | 18 Years - | Immunocore Ltd | |
| Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | NCT03283605 | Head and Neck S... Metastatic Squa... | SBRT Durvalumab Tremelimumab | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | NCT02179671 | Locally Advance... | Gefitinib AZD9291 Selumetinib+Doc... Tremelimumab | 18 Years - 130 Years | AstraZeneca | |
| Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | NCT03007407 | Colorectal Canc... | durvalumab Tremelimumab | 18 Years - | NSABP Foundation Inc | |
| Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | NCT02141542 | Metastatic Mela... | Tremelimumab MEDI3617 | 18 Years - | Dana-Farber Cancer Institute | |
| Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | NCT03959293 | Gastric Adenoca... Gastric Cancer | Durvalumab Tremelimumab FOLFIRI Protoco... | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| ......SMARTEST Trial...... | NCT05380713 | Mesothelioma, M... | Cyclophosphamid... Tremelimumab Durvalumab | 18 Years - 95 Years | University Health Network, Toronto | |
| A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | NCT02519348 | Hepatocellular ... | Tremelimumab Durvalumab Bevacizumab | 18 Years - 99 Years | MedImmune LLC | |
| A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer | NCT03212469 | Head and Neck S... Lung Cancer Oesophageal Can... | Durvalumab Tremelimumab SBRT | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | NCT03871036 | Urothelial Carc... | Tremelimumab Durvalumab Paclitaxel | 18 Years - | The Netherlands Cancer Institute | |
| Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer | NCT05120622 | Bladder Cancer High-Risk Cance... Tremelimumab Durvalumab Non-muscle Inva... | Tremelimumab | - | University of British Columbia | |
| Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | NCT02888743 | Metastatic Colo... Metastatic Lung... Stage IV Colore... Stage IV Lung N... Stage IVA Color... Stage IVB Color... | Durvalumab Radiation Thera... Tremelimumab | 18 Years - | National Cancer Institute (NCI) | |
| Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) | NCT04989218 | Cholangiocarcin... | Novel combinati... | 18 Years - 89 Years | University of Alabama at Birmingham | |
| Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma | NCT03116529 | Soft Tissue Sar... | Combination Rad... | 18 Years - | University of Maryland, Baltimore | |
| A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer | NCT02262741 | Squamous Cell C... | MEDI4736 tremelimumab | 18 Years - 99 Years | MedImmune LLC | |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy | NCT03703297 | Small Cell Lung... | Durvalumab Tremelimumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | NCT04605731 | BCLC Stage B He... BCLC Stage C He... Locally Advance... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Durvalumab Tremelimumab | 18 Years - | City of Hope Medical Center | |
| Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | NCT03923270 | Small Cell Lung... Small-cell Lung... | Durvalumab Tremelimumab Olaparib Pill Thoracic Radiot... Tremelimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC | NCT03202758 | Colorectal Canc... | Durvalumab, Tre... | 18 Years - | Centre Georges Francois Leclerc | |
| A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | NCT03015129 | Endometrial Can... Endometrial Car... Endometrial Car... Endometrial Can... Endometrial Car... | Durvalumab Tremelimumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients | NCT02040064 | Non Small Cell ... | Gefitinib Tremelimumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer | NCT05120622 | Bladder Cancer High-Risk Cance... Tremelimumab Durvalumab Non-muscle Inva... | Tremelimumab | - | University of British Columbia | |
| Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer | NCT05120622 | Bladder Cancer High-Risk Cance... Tremelimumab Durvalumab Non-muscle Inva... | Tremelimumab | - | University of British Columbia | |
| Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | NCT03606967 | Anatomic Stage ... Invasive Breast... Metastatic Trip... | Biopsy Biospecimen Col... Carboplatin Computed Tomogr... Durvalumab Gemcitabine Hyd... Magnetic Resona... Nab-paclitaxel Personalized Sy... Poly ICLC Tremelimumab | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | NCT03075527 | Mesothelioma | Tremelimumab Durvalumab | 18 Years - | Dana-Farber Cancer Institute | |
| Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition | NCT03275597 | Non-small Cell ... Non-small Cell ... | Durvalumab Tremelimumab Stereotactic Bo... | 18 Years - | University of Wisconsin, Madison | |
| Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT03026062 | Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Fall... Refractory Ovar... Refractory Prim... | Durvalumab Tremelimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma | NCT05557838 | Hepatocellular ... | Durvalumab Tremelimumab | 18 Years - | AstraZeneca | |
| Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma | NCT06058663 | Locally Advance... Oligometastatic... Stage III Intra... Stage IV Intrah... Unresectable In... | Angiography Biopsy Biospecimen Col... Computed Tomogr... Durvalumab Magnetic Resona... Positron Emissi... Tremelimumab Yttrium-90 Micr... | 18 Years - | Mayo Clinic | |
| Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | NCT03283605 | Head and Neck S... Metastatic Squa... | SBRT Durvalumab Tremelimumab | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Brain Irradiation and Tremelimumab in Metastatic Breast Cancer | NCT02563925 | Metastatic Brea... | Brain radiother... Tremelimumab HER2 directed t... Durvalumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) | NCT02453282 | Non-Small-Cell ... | MEDI4736 (Durva... MEDI4736 (Durva... Paclitaxel + Ca... Gemcitabine + C... Gemcitabine + C... Pemetrexed + Ci... Pemetrexed + Ca... Tremelimumab | 18 Years - 130 Years | AstraZeneca | |
| Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | NCT05451043 | Pancreatic Canc... Hepatocellular ... Biliary Tract C... Cholangiocarcin... | Durvalumab Gemcitabine Nab paclitaxel Tremelimumab Propranolol Cisplatin | 18 Years - | AHS Cancer Control Alberta | |
| A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | NCT02821754 | Biliary Tract N... Liver Cancer Hepatocellular ... Cholangiocarcin... Bile Duct Cance... | Durvalumab Tremelimumab Trans-arterial ... Radiofrequency ... Cryoablation | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | NCT02762006 | Renal Cell Carc... Kidney Cancer | Durvalumab Tremelimumab | 18 Years - | Case Comprehensive Cancer Center | |
| Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors | NCT02938793 | Cancer Rare Disease | Durvalumab Tremelimumab | 18 Years - | Prisma Health-Upstate | |
| Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) | NCT03043872 | Small Cell Lung... | Durvalumab Tremelimumab Carboplatin Cisplatin Etoposide | 18 Years - 130 Years | AstraZeneca | |
| Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | NCT02794883 | Malignant Gliom... Recurrent Gliob... | Durvalumab Laboratory Biom... Surgical Proced... Tremelimumab | 18 Years - | Northwestern University | |
| Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors | NCT03982173 | Metastatic Colo... Triple Negative... Prostate Adenoc... Stomach Adenoca... Esophageal Aden... | Tremelimumab Durvalumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer | NCT03150836 | Bladder Cancer | Durvalumab Tremelimumab Radiation Thera... | 18 Years - | University of California, San Francisco | |
| TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer | NCT04073160 | Bladder Cancer | Tremelimumab Durvalumab Bladder radiati... Intravesicular ... | 18 Years - | Duke University | |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | NCT02643303 | Head and Neck S... Breast Cancer Sarcoma Merkel Cell Car... Cutaneous T-Cel... Melanoma Renal Cancer Bladder Cancer Prostate Cancer Testicular Canc... Solid Tumor | Durvalumab Tremelimumab Poly-ICLC | 18 Years - | Ludwig Institute for Cancer Research | |
| Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery | NCT02812420 | Hydronephrosis Infiltrating Bl... Infiltrating Bl... Infiltrating Bl... Infiltrating Re... Renal Pelvis Ur... Stage II Bladde... Stage II Renal ... Stage II Ureter... Stage II Urethr... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Durvalumab Therapeutic Con... Tremelimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | NCT02639026 | Metastatic Melanoma Non Small Cell ... Breast Cancer Pancreatic Canc... | Radiotherapy MEDI4736 Tremelimumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | NCT02311361 | Pancreatic Neop... Pancreatic Canc... Cancer of Pancr... Cancer of the P... Pancreas Cancer | Durvalumab Tremelimumab Sterostatic bod... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | NCT02261220 | Advanced Solid ... | MEDI4736 tremelimumab | 18 Years - 99 Years | MedImmune LLC | |
| TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma | NCT04988945 | HCC | TACE SBRT Durvalumab Tremelimumab | 18 Years - | The University of Hong Kong | |
| Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC | NCT03202758 | Colorectal Canc... | Durvalumab, Tre... | 18 Years - | Centre Georges Francois Leclerc | |
| Himalaya Early Access Program | NCT05345678 | Unresectable He... | Durvalumab Tremelimumab | 18 Years - | AstraZeneca | |
| Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma | NCT03116529 | Soft Tissue Sar... | Combination Rad... | 18 Years - | University of Maryland, Baltimore | |
| Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | NCT04585490 | Non Small Cell ... NSCLC, Stage II... Nsclc | Durvalumab Carboplatin Pemetrexed Paclitaxel Cisplatin AVENIO ctDNA Su... Tremelimumab | 18 Years - | Stanford University | |
| A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer | NCT02000947 | NSCLC Non-small Cell ... Lung Cancer | MEDI4736 Tremelimumab tremelimumab | 18 Years - 101 Years | MedImmune LLC | |
| Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors | NCT03081923 | Germ Cell Tumor | Durvalumab Tremelimumab | 18 Years - 75 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | NCT03937830 | Hepatocellular ... Hepatocellular ... Metastatic Hepa... | durvalumab Doxorubicin-Elu... TACE bevacizumab Tremelimumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach | NCT03702179 | Invasive Bladde... | Durvalumab Tremelimumab Radiotherapy | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | NCT02519348 | Hepatocellular ... | Tremelimumab Durvalumab Bevacizumab | 18 Years - 99 Years | MedImmune LLC | |
| A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer | NCT03122509 | Metastatic Colo... | durvalumab tremelimumab Radiotherapy (R... ablation | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) | NCT03043872 | Small Cell Lung... | Durvalumab Tremelimumab Carboplatin Cisplatin Etoposide | 18 Years - 130 Years | AstraZeneca | |
| Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | NCT03606967 | Anatomic Stage ... Invasive Breast... Metastatic Trip... | Biopsy Biospecimen Col... Carboplatin Computed Tomogr... Durvalumab Gemcitabine Hyd... Magnetic Resona... Nab-paclitaxel Personalized Sy... Poly ICLC Tremelimumab | 18 Years - | National Cancer Institute (NCI) | |
| Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma | NCT05557838 | Hepatocellular ... | Durvalumab Tremelimumab | 18 Years - | AstraZeneca | |
| A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | NCT02519348 | Hepatocellular ... | Tremelimumab Durvalumab Bevacizumab | 18 Years - 99 Years | MedImmune LLC | |
| A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) | NCT02616185 | Prostatic Neopl... | PF-06755992 PF-06755990 TDS-IM Electrop... Tremelimumab PF-06801591 PF-06753512 | 18 Years - | Pfizer | |
| Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma | NCT06058663 | Locally Advance... Oligometastatic... Stage III Intra... Stage IV Intrah... Unresectable In... | Angiography Biopsy Biospecimen Col... Computed Tomogr... Durvalumab Magnetic Resona... Positron Emissi... Tremelimumab Yttrium-90 Micr... | 18 Years - | Mayo Clinic | |
| A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | NCT02340975 | Gastric or Gast... | MEDI4736 + trem... MEDI4736 + trem... MEDI4736 Tremelimumab MEDI4736+tremel... MEDI4736 + trem... | 18 Years - 99 Years | MedImmune LLC | |
| Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | NCT03871036 | Urothelial Carc... | Tremelimumab Durvalumab Paclitaxel | 18 Years - | The Netherlands Cancer Institute | |
| Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies | NCT03539822 | Gastric Cancer Esophageal Aden... Hepatocellular ... Colorectal Canc... | Cabozantinib Durvalumab Tremelimumab | 18 Years - | University of Pittsburgh | |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | NCT03277482 | Recurrent Gynec... Metastatic Cerv... Metastatic Ovar... Metastatic Vagi... Metastatic Vulv... Metastatic Endo... Recurrent Cervi... Recurrent Ovari... Recurrent Vagin... Recurrent Vulva... Recurrent Endom... | Durvalumab Tremelimumab Radiation Thera... | 18 Years - | Dana-Farber Cancer Institute | |
| SGI-110 Plus Durvalumab/Tremelimumab in SCLC | NCT03085849 | Extensive-stage... | Durvalumab Tremelimumab SGI-110 | 18 Years - 99 Years | Columbia University | |
| Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer | NCT03122496 | Metastatic Anap... | durvalumab tremelimumab Stereotactic Bo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| ......SMARTEST Trial...... | NCT05380713 | Mesothelioma, M... | Cyclophosphamid... Tremelimumab Durvalumab | 18 Years - 95 Years | University Health Network, Toronto | |
| Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | NCT03057106 | Lung Cancer Met... | Durvalumab Tremelimumab Platinum-Based ... | 18 Years - | Canadian Cancer Trials Group | |
| Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer | NCT02551159 | Squamous Cell C... | MEDI4736 Tremelimumab MEDI4736+Tremel... Cetuximab 5-fluorouracil ... Cisplatin Carboplatin | 18 Years - 130 Years | AstraZeneca | |
| Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver | NCT03005002 | Metastatic Carc... MLH1 Gene Mutat... MSH6 Gene Mutat... PMS2 Gene Mutat... Stage IV Colore... Stage IVA Color... Stage IVB Color... | Durvalumab Laboratory Biom... Tremelimumab | 19 Years - | City of Hope Medical Center | |
| Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | NCT02879162 | Advanced Rare T... | Durvalumab Tremelimumab | 16 Years - | Canadian Cancer Trials Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
